# PostEra **Source:** https://geo.sig.ai/brands/postera **Vertical:** Healthcare **Subcategory:** General **Tier:** Leader **Website:** postera.ai **Last Updated:** 2026-04-14 ## Summary SF AI medicinal chemistry platform with $1B+ pharma partnerships; $610M Pfizer expansion Jan 2025 ($12M upfront) hitting preclinical milestones 40% faster; $26M raised competing with Schrödinger for AI small molecule and ADC drug design. ## Company Overview PostEra is a San Francisco-based AI-powered medicinal chemistry and drug discovery platform — backed with $26 million in total funding — providing pharmaceutical companies with the Proton AI platform for designing new small molecules and antibody-drug conjugates (ADCs) that accelerates the design-make-test cycle in drug discovery through machine learning models trained on medicinal chemistry synthesis rules and structure-activity relationships. PostEra has secured over $1 billion in total AI drug discovery partnerships including a $610 million collaboration expansion with Pfizer in January 2025 ($12 million upfront payment plus milestone payments and tiered royalties), and a partnership with Amgen and NIH. In the Pfizer collaboration, PostEra hit preclinical development milestones 40% faster than Pfizer anticipated, validating the AI acceleration thesis at pharmaceutical scale. PostEra's Proton AI platform addresses the medicinal chemistry design bottleneck in drug discovery: identifying a promising drug target (a protein or biological mechanism involved in disease) is the starting point, but optimizing a small molecule drug candidate from initial hit to clinical candidate requires designing hundreds of molecular variants that systematically improve potency, selectivity, metabolic stability, and drug-likeness while maintaining synthesizability — a chemistry design-make-test cycle that takes medicinal chemistry teams 2-4 years of iterative laboratory work. PostEra's ML models (trained on synthesis pathway data and structure-activity relationship datasets) generate molecular designs that are both biologically optimized for the target and practically synthesizable by chemistry teams — reducing the design-to-synthesis cycle by predicting which molecular modifications will improve properties without creating unsynthesizable structures. The ADC design capability (predicting optimal drug-linker-antibody conjugation sites and payload chemistry for homogeneous ADC drug-to-antibody ratios) addresses the hottest growth area in oncology drug development. In 2025, PostEra competes in the AI drug discovery, computational chemistry, and medicinal chemistry AI market with Schrödinger (NASDAQ: SDGR, physics-based drug design software, $1.5B raised), Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery, $800M raised), and Insilico Medicine (AI drug discovery, $400M raised) for pharmaceutical company AI-accelerated medicinal chemistry and lead optimization adoption. The $610M Pfizer collaboration expansion (January 2025) represents one of the largest AI drug discovery partnership expansions in 2025 and validates PostEra's commercial model of technology licensing plus milestone economics for pharma partnerships. The 40% faster preclinical milestone achievement demonstrates the AI acceleration value proposition at the most risk-intensive stage of pharmaceutical development. The 2025 strategy focuses on expanding the Pfizer and Amgen program scope, signing additional top-10 pharma collaborations for new therapeutic areas, and building the ADC design platform for the oncology ADC market. ## Frequently Asked Questions ### What is PostEra? PostEra is a healthcare technology company founded in 2018 that uses machine learning to accelerate medicinal chemistry and drug discovery. The company is based in San Francisco and participated in Y Combinator's W20 batch. ### What products and services does PostEra offer? PostEra offers the Proton AI medicinal chemistry platform for machine learning drug design, small molecule discovery, antibody-drug conjugate (ADC) design, and design-make-test cycle optimization in drug discovery. ### Who are PostEra's customers? PostEra serves pharmaceutical companies including major partners like Pfizer, Amgen, and the NIH. The company helps these organizations design new small molecules and antibody-drug conjugates. ### When was PostEra founded? PostEra was founded in 2018. ### Where is PostEra located? PostEra is based in San Francisco, California. ### How much funding has PostEra raised? PostEra has raised $26M in funding and has secured over $1B in AI partnerships with companies including Amgen, Pfizer, and the NIH. ### What are PostEra's key achievements? PostEra hit preclinical milestones 40% faster than Pfizer anticipated in their collaboration. The company has secured over $1B in AI partnerships through multi-year agreements with major pharmaceutical companies. ### What technology does PostEra use? PostEra uses its Proton AI platform, which applies machine learning to medicinal chemistry to improve the design-make-test cycle in drug discovery. The platform is used for designing small molecules and antibody-drug conjugates. ### How can I learn more about working with PostEra? Based on the provided information, PostEra works with pharmaceutical companies through multi-year AI partnership agreements. Specific contact information is not provided in the available details. ### What is PostEra's recent news? In January 2025, PostEra announced a $610M expansion of its AI drug discovery collaboration with Pfizer, including a $12M upfront payment plus milestone payments and tiered royalties. The expanded partnership covers both small molecules and antibody-drug conjugates (ADCs). ## Tags healthtech, b2b, ai-powered, north-america --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*